trenbolone enanthate stack

The lowest level of white blood cell trenbolone enanthate stack count and platelets observed after 7-14 days, the restoration of blood picture is usually 21 days after completion of the course. From the digestive system: nausea and vomiting. Rarely – stomatitis, abnormal liver function, usually manifests itself in the form of increased liver enzymes and / or serum bilirubin. From the urinary system: hemorrhagic cystitis, dysuria, frequent urination and other symptoms of inflammation of the bladder (blood in the urine, painful urination ), renal dysfunction (increased concentration of creatinine and urea in serum, decreased trenbolone enanthate stack creatinine clearance, glycosuria). There may also be proteinuria and metabolic acidosis. From the nervous system: disorientation, confusion, hallucinations, agitation fatigue, encephalopathy; less often – dizziness; rarely – seizures, coma, peripheral neuropathy. Reproductive system: dysfunction of the sex glands (azoospermia, amenorrhea). Skin and skin appendages: reversible alopecia, photosensitivity Local reactions: redness, swelling or pain at the injection site Other: cardiotoxic action, immunosuppression, infectious complications, slowing the rate of healing of wounds, pulmonary symptoms (cough or shortness of breath), fever, allergic reactions,faster development and pronounced the major side effects. Treatment: symptomatic, with obligatory use of mesna.

Interaction with other medicinal products
In an application with drugs that cause myelotoxic, neurotoxic and nephrotoxic effects may be increased side effects.
When used together with inducers of microsomal liver enzymes may increase the formation of alkylating metabolites. In an application enhances the hypoglycemic effect of hypoglycemic drugs. Allopurinol strengthens myelosuppression. Mesna reduces nephrotoxicity.
Ifosfamide may enhance skin reactions to radiation.
Simultaneous treatment with warfarin can reduce blood clotting and increase the risk of bleeding.

special instructions

  • Before treatment is necessary readjustment of foci of chronic infection and correction of possible electrolyte imbalance.
  • At the time of treatment should be regularly monitored picture peripheral blood (especially paying attention to the number of neutrophils and platelets), laboratory parameters of liver function, kidney and urine regularly for the presence of red blood cells, the appearance of which may precede the development of hemorrhagic cystitis.
  • If impairment of renal function and urinary flow rate may increase the toxic effect of the drug on the central nervous system, and therefore you may need to reduce the dose of ifosfamide.
  • To ensure the elimination of uric acid patients should consume enough fluids.
  • At the first signs of inflammation of the bladder or the appearance of blood in the urine, ifosfamide therapy should be discontinued.
  • In the treatment with ifosfamide is trenbolone enanthate stack possible to suppress the natural defense mechanisms, the development of antibodies in the patient’s body in response to the vaccine may be reduced.
  • Women and men during treatment and for 3 months after treatment with ifosfamide should use reliable methods of contraception.

    Effects on ability to drive and use machines
    During drug therapy may experience nausea and vomiting, as well as the phenomenon of encephalopathy, which may affect the ability to drive a car or work with other mechanisms. Therefore, you should refrain from driving and other vehicles! It should also work with power tools and machinery!

    Product form
    Powder for solution for infusion 0.2 g; 0.5 g; 1.0 g; 2.0 g to 0.2 g or 0.5 g vials of glass tubes for packaging and storage of medicines 10 ml capacity hermetically sealed with rubber stoppers mixture crimped aluminum caps.
    As 1.0 g or 2.0 g in bottles with a capacity of 25 ml injection of imported flint glass or 50 ml, respectively, sealed with rubber stoppers made ??of rubber mixture, crimped caps aluminum.
    1, 5 or 10 vials, together with instructions trenbolone enanthate stack for use in a stack of cardboard boxed or chromium-ersatz.
    50 vials with 10 instructions for use in a box made ??of cardboard for consumer packaging (for hospitals).

    Storage conditions
    List B.
    In dry, dark place at a temperature no higher than 25 ° C. In the reach of children!

    Shelf life
    2 years.
    Do not use after the expiry date stated on the package.

  •  

    where to get clenbuterol